In contrast to plasma samples with high fMet levels, the FPR1 antagonist CsH could not inhibit neutrophil activation induced by SSc plasma samples with low fMet levels (CD66b; p=0.5 and CD11b; p=0.5). Here, CEACAM8 is linked to systemic sclerosis.